Vanroey M - Search Results

1

The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration.

Prell RA, Gearin L, Simmons A, Vanroey M, Jooss K. Prell RA, et al. Among authors: vanroey m. Cancer Immunol Immunother. 2006 Oct;55(10):1285-93. doi: 10.1007/s00262-005-0116-4. Epub 2006 Jan 12. Cancer Immunol Immunother. 2006. PMID: 16408214 Free PMC article.

2

Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.

Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K, Huan Tu G, Prell R, VanRoey MJ, Simmons AD, Jooss K. Li B, et al. Clin Cancer Res. 2006 Nov 15;12(22):6808-16. doi: 10.1158/1078-0432.CCR-06-1558. Clin Cancer Res. 2006. PMID: 17121902

3

Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy.

Li B, VanRoey MJ, Jooss K. Li B, et al. Clin Immunol. 2007 May;123(2):155-65. doi: 10.1016/j.clim.2007.01.002. Epub 2007 Feb 22. Clin Immunol. 2007. PMID: 17320482

4

GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action.

Simmons AD, Li B, Gonzalez-Edick M, Lin C, Moskalenko M, Du T, Creson J, VanRoey MJ, Jooss K. Simmons AD, et al. Among authors: vanroey mj. Cancer Immunol Immunother. 2007 Oct;56(10):1653-65. doi: 10.1007/s00262-007-0315-2. Epub 2007 Apr 5. Cancer Immunol Immunother. 2007. PMID: 17410360 Free PMC article.

5

Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity.

Simmons AD, Moskalenko M, Creson J, Fang J, Yi S, VanRoey MJ, Allison JP, Jooss K. Simmons AD, et al. Among authors: vanroey mj. Cancer Immunol Immunother. 2008 Aug;57(8):1263-70. doi: 10.1007/s00262-008-0451-3. Epub 2008 Jan 31. Cancer Immunol Immunother. 2008. PMID: 18236040 Free PMC article.

6

Administration of IFN-alpha enhances the efficacy of a granulocyte macrophage colony stimulating factor-secreting tumor cell vaccine.

Prell RA, Li B, Lin JM, VanRoey M, Jooss K. Prell RA, et al. Among authors: vanroey m. Cancer Res. 2005 Mar 15;65(6):2449-56. doi: 10.1158/0008-5472.CAN-04-1975. Cancer Res. 2005. PMID: 15781661

7

Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.

Li B, Lin J, Vanroey M, Jure-Kunkel M, Jooss K. Li B, et al. Among authors: vanroey m. Clin Immunol. 2007 Oct;125(1):76-87. doi: 10.1016/j.clim.2007.07.005. Epub 2007 Aug 13. Clin Immunol. 2007. PMID: 17706463

8

Enhancement of the anti-tumor efficacy of a GM-CSF-secreting tumor cell immunotherapy in preclinical models by cytosine arabinoside.

Lin JM, Li B, Rimmer E, VanRoey M, Jooss K. Lin JM, et al. Among authors: vanroey m. Exp Hematol. 2008 Mar;36(3):319-28. doi: 10.1016/j.exphem.2007.11.005. Exp Hematol. 2008. PMID: 18279719 Free article.

9

Lymphocyte activation gene-3 fusion protein increases the potency of a granulocyte macrophage colony-stimulating factor-secreting tumor cell immunotherapy.

Li B, VanRoey M, Triebel F, Jooss K. Li B, et al. Among authors: vanroey m. Clin Cancer Res. 2008 Jun 1;14(11):3545-54. doi: 10.1158/1078-0432.CCR-07-5200. Clin Cancer Res. 2008. PMID: 18519788

10

Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.

Li B, VanRoey M, Wang C, Chen TH, Korman A, Jooss K. Li B, et al. Among authors: vanroey m. Clin Cancer Res. 2009 Mar 1;15(5):1623-34. doi: 10.1158/1078-0432.CCR-08-1825. Epub 2009 Feb 10. Clin Cancer Res. 2009. PMID: 19208793

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

30 results

Search Page

Filters